Samsara Bio Capital, LLC Allakos Inc. Transaction History

Samsara Bio Capital, LLC

$326 Million
Q4 2024

A detailed history of Samsara Bio Capital, LLC transactions in Allakos Inc. stock. As of the latest transaction made, Samsara Bio Capital, LLC holds 172,089 shares of ALLK stock, worth $43,022. This represents 0.06% of its overall portfolio holdings.

Number of Shares

172,089

Previous 172,089 -0.0%

Holding current value

$43,022

Previous $111,000 87.39%

% of portfolio

0.06%

Previous 0.06%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $739,982 - $1.42 Million	172,089 New	172,089 $765,000
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $1.98 Million - $2.85 Million	25,830 Added 17.66%	172,089 $18.2 Million
Q4 2020 Feb 17, 2021	SELL	$79.58 - $152.45 $3.67 Million - $7.02 Million	-46,075 Reduced 23.96%	146,259 $20.5 Million
Q3 2020 Nov 16, 2020	SELL	$66.43 - $90.99 $3.42 Million - $4.69 Million	-51,534 Reduced 21.13%	192,334 $15.7 Million
Q2 2020 Aug 14, 2020	SELL	$44.04 - $80.69 $1.19 Million - $2.19 Million	-27,097 Reduced 10.0%	243,868 $17.5 Million
Q1 2020 May 15, 2020	BUY	$44.49 - $93.39 $1.27 Million - $2.66 Million	28,460 Added 11.74%	270,965 $12.1 Million
Q4 2019 Feb 18, 2020	SELL	$66.49 - $137.73 $2.97 Million - $6.16 Million	-44,700 Reduced 15.56%	242,505 $23.1 Million
Q3 2019 Nov 14, 2019	SELL	$31.0 - $89.73 $4.95 Million - $14.3 Million	-159,700 Reduced 35.73%	287,205 $22.6 Million
Q1 2019 May 15, 2019	SELL	$33.79 - $51.99 $387,267 - $595,857	-11,461 Reduced 2.5%	446,905 $18.1 Million
Q4 2018 Feb 14, 2019	BUY	$31.59 - $62.65 $14.5 Million - $28.7 Million	458,366 New	458,366 $24 Million

Others Institutions Holding ALLK

# of Institutions

Shares Held

68.8M

Call Options Held

20.9K

Put Options Held

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $21.2M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Samsara Bio Capital, LLC with notifications on news.

Account

Samsara Bio Capital, LLC Allakos Inc. Transaction History